| LH |
Report |
Enterprise revenue |
BEAT |
pred ~$3.76B vs. cons $3.71B |
MEDIUM |
| LH |
Report |
Adjusted EPS |
BEAT |
pred ~$4.87 vs. cons $4.79 |
MEDIUM |
| LH |
Report |
BLS quarterly book-to-bill |
BEAT |
pred ~1.04x vs. cons 1.00x |
MEDIUM |
| LH |
Guide |
FY2026 enterprise revenue guidance |
BETTER |
guide ~$14.78B vs. cons $14.73B (FY2026) |
MEDIUM |
| LH |
Guide |
FY2026 adjusted EPS guidance |
BETTER |
guide ~$18.12 vs. cons $18.03 (FY2026) |
MEDIUM |
| LH |
Guide |
FY2026 free-cash-flow guidance |
UNCHANGED |
guide ~$1.30B vs. cons $1.30B (FY2026) |
MEDIUM |
| LH |
Return |
Day-1 residual (stock − beta × S&P 500) |
+3.2% |
— |
MEDIUM |
| LH |
Return |
5-day cumulative residual |
+4.5% (FOLLOW-THROUGH) |
A ~$0.09 FY2026 EPS-guide lift versus the current $18.03 midpoint, together with a book-to-bill recovery to ~1.04x versus 1.00x, supports modest upward out-period estimates despite a largely anticipated quarterly beat. |
MEDIUM |